Q-Med was founded 1987 with the vision to develop the world's first filler based on non-animal hyaluronic acid (HA) to restore and improve skin. The research led to the launch of Restylane in 1996, which was approved in the United States by the US Government (FDA) in 2003. This was the beginning of a success story.
In 2011, Q-Med was purchased by Galderma, a Swiss pharmaceutical company that specializes in skin care. The Uppsala site is now Galderma's global center for Aesthetics with activities in the development, manufacturing and marketing of world-leading products such as Restylane®, Azzalure® and Sculptra®.
Galderma in Uppsala currently employs about 450 employees making the site one of the largest private employers in the Uppsala municipality. Here, experts work on medical devices and also pharmaceuticals, in more than 120 different occupational categories, from laboratory engineers to process operators. Our employees have many different backgrounds, everything from doctors, pharmacists, chemists, civil engineers and biochemists, but also marketers, economists and IT specialists, etc..
The Uppsala site consists of 13 buildings, and our modern premises are located along the river Fyris, only 10 minutes by bike from Uppsala Central Station. We apply the highest safety and quality standards in everything we do and especially in our production facility. We are certified according to ISO 14001, ISO 13485, OHSAS18001, FDA (USA), SFDA (China), DEKRA (Europe), Health Canada, TGA (Australia).
The site also includes Galderma Nordics AB, which is responsible for the sales of Galderma products in the Nordic countries, such as Cetaphil® (skin care), Basiderm® (acne), Rozex® (rosacea), Loceryl® (nail fungus), Actinica® (skin cancer) and of course Restylane® and Azzalure® (aesthetic).
Galderma in Uppsala participates in local organizations such as Uppsala BIO, World Class Uppsala, Young Enterprise in Uppsala, and Uppsala Climate Protocol.